Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (26)

Search Parameters:
Authors = Dimitrios Christopoulos

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
15 pages, 979 KiB  
Article
Unveiling the Diagnostic Significance of Calprotectin in Serous Ovarian Carcinoma
by Alkis Matsas, Eleni Stamoula, Konstantinos Kontzoglou, Makarios Eleftheriades, Sophia Tsokkou, Panagiotis Christopoulos, Theodoros Panoskaltsis, Eleni Polydorou, Ioannis Sotiropoulos, Theodore Troupis and Dimitrios C. Iliopoulos
Life 2025, 15(7), 1080; https://doi.org/10.3390/life15071080 - 8 Jul 2025
Viewed by 604
Abstract
Introduction: Ovarian cancer (OC) is one of the most common gynecologic malignancies and has the highest mortality rate among them. OC has a multifactorial pathogenesis and is characterized by silent onset, progression, and late-stage detection. Therefore, accurate and early detection is of [...] Read more.
Introduction: Ovarian cancer (OC) is one of the most common gynecologic malignancies and has the highest mortality rate among them. OC has a multifactorial pathogenesis and is characterized by silent onset, progression, and late-stage detection. Therefore, accurate and early detection is of great importance in order to improve survival rates. Emerging evidence reveals that tumor markers are valuable diagnostic and monitoring tools. In this study, we evaluated the aforementioned potential of three markers CA-125, CA 15-3, and serum Calprotectin. CA-125 is a protein that is found elevated in cases of ovarian, breast, and lung cancer. Cancer Antigen 15-3 (CA 15-3) is a protein detected in high levels in women with breast cancer and ovarian cancer and it is significantly elevated in patients with metastasis and recurrence of OC. Calprotectin is a protein released from activated neutrophils, related to inflammatory conditions and can be a potential immune-mediated marker in OC. Purpose: The purpose of this study was to explore the significance of serum calprotectin, CA-125, and CA 15-3 in women diagnosed with serous OC. Methodology: Thirty-eight (38) women with diagnosed OC were included in this research as the study group and twenty-seven (27) healthy women with no history or current diagnosis of OC were included in the control group. Women in both groups shared similar past histories to avoid any other parameters interfering with the study. Our study group was further subdivided into early stage and advanced stage patients. Blood samples were collected from all women of both groups and were examined using ELISA kits to evaluate the levels of the above markers. Results: When comparing patients versus control patients, those with OC exhibited higher levels of Calprotectin compared to healthy individuals. Additionally, Calprotectin showed a statistically significant elevation between the control group and advanced patients. CA-125 remains the current standard of care biomarker exhibiting 90% sensitivity, whereas sensitivities in Calprotectin and CA 15-3 were 60% and 50%, respectively. Conclusions: Serum CA-125 remains the single most valuable biomarker for ovarian cancer, having the highest statistical significance, correlation with disease stage, detecting both early or advanced patients, and sensitivity of 90%. It appears to be a promising inflammatory biomarker in the early diagnosis of ovarian cancer, showing an elevation in patients, while CA 15-3 provides moderate complementary information and exhibits inferior sensitivity when compared to both CA-125 and Calprotectin. The latter appears to be a promising marker and further studies could show if its addition to established protocols could improve early detection, disease progression, or risk stratification. Calprotectin enhances the detection range for ovarian cancer when used alongside CA-125, while this combined approach detected a greater proportion of patients than CA-125 alone, indicating improved diagnostic potential. Full article
(This article belongs to the Section Medical Research)
Show Figures

Figure 1

18 pages, 1357 KiB  
Article
Dramatic Deterioration of Subclinical Hyperparathyroidism in Children and Adolescents During the Post-COVID-19 Period
by Maria Loutsou, Eleni Dermitzaki, Rodis D. Paparodis, Aspasia N. Michoula, Nicholas Angelopoulos, Panagiotis Christopoulos, Stavros Diamantopoulos, George Mastorakos, Ioanna N. Grivea and Dimitrios T. Papadimitriou
Diseases 2025, 13(7), 198; https://doi.org/10.3390/diseases13070198 - 27 Jun 2025
Viewed by 404
Abstract
Background: Vitamin D is a steroid hormone, essential for the immune system and bone health. Since the sun is meant to provide at least 80% of daily vitamin D requirements, the COVID-19 pandemic is likely to have induced a considerable influence on calcium [...] Read more.
Background: Vitamin D is a steroid hormone, essential for the immune system and bone health. Since the sun is meant to provide at least 80% of daily vitamin D requirements, the COVID-19 pandemic is likely to have induced a considerable influence on calcium metabolism. Methods: We analyzed data from 1138 children, seen in an outpatient pediatric endocrinology clinic from 2022–2023. Vitamin D status was classified as deficiency if 25(OH)D ≤ 20 ng/mL, insufficiency < 30 ng/mL, and sufficiency ≥ 30 ng/mL. Results: Overall, 60.8% of children had vitamin D deficiency or insufficiency worsened with age (p < 0.005), and with adolescent males having higher 25(OH)D concentrations than females (p < 0.05). A negative correlation was found between 25(OH)D and BMI SDS (R2 = 0.02, p < 0.001), and 25(OH)D concentrations varied seasonally, decreasing in winter. Subclinical hyperparathyroidism [parathyroid hormone (PTH) > 45 pg/mL) and normal calcium] was found in 21.5% of children, with 73.5% of them being vitamin D deficient or insufficient. A negative correlation between PTH and 25(OH)D was observed, with PTH plateauing at 25(OH)D above 40 ng/mL (p < 0.001). Conclusions: Compared to the pre-pandemic data (2016–2018), with only 5.1% of children having subclinical hyperparathyroidism (p < 0.001), these findings suggest a marked deterioration in vitamin D status and calcium metabolism in children, with possible unforeseen consequences for bone, immune, and general health. Full article
Show Figures

Figure 1

8 pages, 797 KiB  
Brief Report
Biologic Agents in Idiopathic Hypereosinophilic Syndrome
by Ourania Papaioannou, Fotios Sampsonas, Panagiota Tsiri, Vasilina Sotiropoulou, Ioannis Christopoulos, Dimitrios Komninos and Argyrios Tzouvelekis
Pharmaceuticals 2025, 18(4), 543; https://doi.org/10.3390/ph18040543 - 8 Apr 2025
Viewed by 740
Abstract
Background: Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by the presence of marked eosinophilia resulting in end organ damage. The diagnostic approach is multidisciplinary and treatment goals include reductions in flares and eosinophils with minimal drug-related side effects. Results: [...] Read more.
Background: Hypereosinophilic syndrome (HES) is a heterogeneous group of rare disorders defined by the presence of marked eosinophilia resulting in end organ damage. The diagnostic approach is multidisciplinary and treatment goals include reductions in flares and eosinophils with minimal drug-related side effects. Results: Eleven patients (n = 11) with a diagnosis of idiopathic HES were included in the study [M/F: 6/5, median age: 54 (95% CI: 38.2 to 68.5), smokers/never smokers: 5/6]. Asthma was present in the majority of them (n = 8, 72.7%); four patients (n = 4, 36.4%) presented with eosinophilic pleural effusions, two patients (n = 2, 18.2%) with cardiac arrhythmias, and one with bilateral eyelid angioedema. Eight patients (72.7%) were treated with mepolizumab (300 mg/month) and three (27.3%) with benralizumab (30 mg/4 weeks). The median values of eosinophils at baseline and 12 months after initiation of biologic agent were 3000 (95% CI: 2172 to 11,365) K/μL and 50 (95% CI: 3 to 190) K/μL, respectively, p = 0.0002. All patients with concomitant asthma (n = 8) experienced elimination of asthma flares, asthma control (ACQ < 0.75), functional improvement (mean ΔFEV1: 857 ± 594 mL), and an 82% reduction in oral corticosteroids, p = 0.0001. Materials and Methods: Patients with highly characterized idiopathic HES treated with anti-eosinophilic agents between 1 October 2019 and 1 October 2023 were retrospectively included in the study. The aim of this study was to present clinical, laboratory, and functional features and outcomes in patients with thoroughly investigated idiopathic HES treated with biologic agents targeting eosinophils. Conclusions: Biologic agents in patients with idiopathic HES—following thorough diagnostic investigation—are both safe and effective, sparing the toxicity of immunosuppressive agents. Real-life data from larger registries are greatly anticipated. Full article
(This article belongs to the Special Issue Drug Candidates for Allergic Diseases)
Show Figures

Figure 1

14 pages, 10188 KiB  
Article
Data-Driven Energy Analysis for a Set of Rooftop Photovoltaic Systems Featuring Different Installation Characteristics: A Pairwise, Early-Life Performance Comparison
by Konstantinos Christopoulos, Dimitrios Zafirakis, Kosmas A. Kavadias and John K. Kaldellis
Energies 2025, 18(7), 1677; https://doi.org/10.3390/en18071677 - 27 Mar 2025
Viewed by 311
Abstract
The specific research presents a detailed, data-driven energy analysis on the early-life operation of two rooftop photovoltaic (PV) systems. The two PV systems examined are operated under the Net Metering scheme and are found in close proximity, within the geographical boundaries of a [...] Read more.
The specific research presents a detailed, data-driven energy analysis on the early-life operation of two rooftop photovoltaic (PV) systems. The two PV systems examined are operated under the Net Metering scheme and are found in close proximity, within the geographical boundaries of a small-scale remote island on the Southeastern part of the Aegean Sea, Greece. The systems feature similar PV technology and capacity, i.e., 3.5 kWp vs. 5 kWp, but differ in terms of installation characteristics; thus, they offer an interesting case for pairwise comparison. Supported by the exploitation of a wealthy set of data, a detailed energy analysis is conducted, with our results providing useful insights on the seasonal performance variation of the two systems and its determinants, reflecting on the different siting and installation characteristics of the former. Full article
Show Figures

Figure 1

11 pages, 1563 KiB  
Brief Report
Real-World Evidence of Administration of Biologic Agents in Patients with Severe Asthma: An Analysis of the Respiratory Department of University Hospital of Patras Asthma Registry
by Ourania Papaioannou, Ioannis Christopoulos, Panagiota Tsiri, Fotios Sampsonas, Kyriakos Karkoulias, Dimosthenis Lykouras, Vasilina Sotiropoulou, Eva Theohari, Dionysios Papalexatos, Dimitrios Komninos, Antonios Christopoulos and Argyrios Tzouvelekis
J. Clin. Med. 2025, 14(7), 2174; https://doi.org/10.3390/jcm14072174 - 22 Mar 2025
Viewed by 999
Abstract
Background: Real-world data on currently used biologic agents in patients with severe asthma are lacking. Methods: In this retrospective study, we recorded between 16 May 2020 and 31 December 2024 consecutive patients who presented to our asthma outpatient clinic received a diagnosis of [...] Read more.
Background: Real-world data on currently used biologic agents in patients with severe asthma are lacking. Methods: In this retrospective study, we recorded between 16 May 2020 and 31 December 2024 consecutive patients who presented to our asthma outpatient clinic received a diagnosis of uncontrolled severe asthma and were treated with biologic agents. Outcomes included a comparison of disease phenotypic characteristics, as well as asthma control, lung function, longitudinal use of corticosteroids, and hospitalizations due to exacerbations at baseline and post-biologic treatment at 6-month follow-up. Results: We identified 80 patients with uncontrolled severe asthma treated with biologic agents. The median age (95% CI) at the time of diagnosis was 67.0 (61.0 to 70.0) years. Most patients were female (65.0%, n = 52) and never smokers (51.3%, n = 41). The median value of ACT (95% CI) was 15 (15 to 16) at the time of diagnosis. The mean FEV1% predicted ±SD at the baseline was 68.9 ± 22.0. The median value of blood eosinophils (95% CI) was 365 (252 to 448) K/μL in the overall population. One-third (36.3%) of patients were hospitalized due to severe asthma exacerbation in the previous year. Longitudinal use of oral corticosteroids was recorded in 11.3% of included patients. Three patients (3.8%) were treated with omalizumab, 23 patients (28.8%) with mepolizumab, 33 patients (41.2%) with benralizumab and 21 patients (26.2%) with tezepelumab. The median value of ACT (95% CI) post-biologic treatment at 6-month follow-up was 20 (20 to 21), p < 0.0001. The mean FEV1% predicted ±SD at 6-month follow-up was 77.6 ± 25.2, p = 0.12. The median value of blood eosinophils (95% CI) 6 months after initiation of biologic treatment was 100 (40 to 121) K/μL, p < 0.0001. Elimination of hospitalizations due to asthma flares was recorded in 97.5% of patients (p < 0.0001). With regard to the longitudinal use of oral corticosteroids, we noticed that 96.2% of patients achieved discontinuation. No treatment-related adverse events were noticed. Conclusions: The administration of current biologic agents in patients with severe asthma seems to be both effective and safe, sparing the toxicity of oral corticosteroids. Full article
(This article belongs to the Section Respiratory Medicine)
Show Figures

Figure 1

13 pages, 537 KiB  
Review
Advancements in Hysteroscopic Diagnosis and Management of Endometritis
by Alkis Matsas, Dimitrios Stefanoudakis, Georgia Kotsira, Sofoklis Stavros, Spyridon Gkoufas, Nikoletta Vrettou, Smaragdi Christopoulou and Panagiotis Christopoulos
Diagnostics 2025, 15(3), 243; https://doi.org/10.3390/diagnostics15030243 - 21 Jan 2025
Cited by 1 | Viewed by 1714
Abstract
Infertility remains a complex clinical challenge, with intrauterine pathologies contributing to a significant percentage of in vitro fertilization (IVF) failures. Chronic endometritis (CE) has gained attention due to its potential association with unexplained infertility and recurrent miscarriage. This review explores the role of [...] Read more.
Infertility remains a complex clinical challenge, with intrauterine pathologies contributing to a significant percentage of in vitro fertilization (IVF) failures. Chronic endometritis (CE) has gained attention due to its potential association with unexplained infertility and recurrent miscarriage. This review explores the role of hysteroscopy in diagnosing and treating CE. The endometrium undergoes dynamic changes orchestrated by ovarian steroids, and disturbances may lead to CE, characterized by plasma cell infiltration. Diagnosis traditionally relies on histopathologic examination, but hysteroscopy offers real-time imaging, revealing the specific macroscopic alterations associated with CE. However, diagnostic accuracy varies, prompting the need for standardized criteria. CE has been linked to poor reproductive outcomes, emphasizing the importance of effective treatment. Antibiotic therapy is a common approach, with doxycycline as the first-line regimen. Hysteroscopic polypectomy, targeting non-infectious CE, emerges as a promising treatment, demonstrating fertility benefits. The review underscores the significance of hysteroscopy in diagnosing and treating CE, providing insights into its impact on reproductive outcomes in infertile women. Further prospective studies are needed to validate these findings and establish unified diagnostic criteria. Full article
(This article belongs to the Special Issue Advances in Diagnostic and Operative Hysteroscopy)
Show Figures

Figure 1

14 pages, 1219 KiB  
Review
Immunotherapy in Cervical and Endometrial Cancer: Current Landscape and Future Directions
by Dimitrios Stefanoudakis, Evaggelia Karopoulou, Alkis Matsas, Georgia Anna Katsampoula, Ermioni Tsarna, Eleni Stamoula and Panagiotis Christopoulos
Life 2024, 14(3), 344; https://doi.org/10.3390/life14030344 - 6 Mar 2024
Cited by 15 | Viewed by 5423
Abstract
Gynecological cancers pose a significant burden on women’s health worldwide, necessitating innovative treatment approaches. Immunotherapy has emerged as a promising strategy, harnessing the body’s immune system to combat cancer. This review aims to provide a comprehensive overview of the current landscape and future [...] Read more.
Gynecological cancers pose a significant burden on women’s health worldwide, necessitating innovative treatment approaches. Immunotherapy has emerged as a promising strategy, harnessing the body’s immune system to combat cancer. This review aims to provide a comprehensive overview of the current landscape and future directions of immunotherapy in cervical and endometrial cancer. Methods: A thorough literature search was conducted to identify relevant studies and clinical trials. The main methods and treatments employed in immunotherapy for cervical and endometrial cancer, including immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapies, are briefly described. Results: Immune checkpoint inhibitors, such as anti-PD-1/PD-L1 antibodies, have shown remarkable clinical efficacy in certain gynecological malignancies, particularly in advanced or recurrent cases. Additionally, ongoing research on cancer vaccines and adoptive cell therapies holds promise for personalized and targeted treatment options. Full article
(This article belongs to the Special Issue Multi-disciplinary Approaches against Female Diseases)
Show Figures

Figure 1

24 pages, 2208 KiB  
Review
A Review of the Energy Storage Systems of Non-Interconnected European Islands
by Maria Fotopoulou, Panagiotis Pediaditis, Niki Skopetou, Dimitrios Rakopoulos, Sotirios Christopoulos and Avraam Kartalidis
Sustainability 2024, 16(4), 1572; https://doi.org/10.3390/su16041572 - 13 Feb 2024
Cited by 32 | Viewed by 3297
Abstract
The ongoing energy transition has caused a paradigm shift in the architecture of power systems, increasing their sustainability with the installation of renewable energy sources (RES). In most cases, the efficient utilization of renewable energy requires the employment of energy storage systems (ESSs), [...] Read more.
The ongoing energy transition has caused a paradigm shift in the architecture of power systems, increasing their sustainability with the installation of renewable energy sources (RES). In most cases, the efficient utilization of renewable energy requires the employment of energy storage systems (ESSs), such as batteries and hydro-pumped storage systems. The need for ESS becomes more apparent when it comes to non-interconnected power systems, where the incorporation of stochastic renewables, such as photovoltaics (PV) systems, may more frequently reduce certain power quality indicators or lead to curtailments. The purpose of this review paper is to present the predominant core technologies related to ESSs, along with their technical and life cycle analysis and the range of ancillary services that they can provide to non-interconnected power systems. Also, it aims to provide a detailed description of existing installations, or combinations of installations, in non-interconnected European islands. Therefore, it provides an overview and maps the current status of storage solutions that enhance the sustainable environmentally friendly operation of autonomous systems. Full article
(This article belongs to the Special Issue Advances in Renewable Energy Production and Storage)
Show Figures

Graphical abstract

7 pages, 3221 KiB  
Proceeding Paper
Self-Consumption and Market Integration Balance Analysis for RES–Battery Electricity Prosumers in Greece
by Konstantinos Christopoulos, Iliana Stefanidi, Kosmas Kavadias and Dimitrios Zafirakis
Environ. Sci. Proc. 2023, 26(1), 182; https://doi.org/10.3390/environsciproc2023026182 - 7 Sep 2023
Cited by 1 | Viewed by 928
Abstract
Increased interest is demonstrated recently in the emergence of prosumer schemes for the residential sector on the basis of combined RES and storage configurations. Primarily, such schemes aim to increase energy autonomy for end users. Despite providing an alternative supply solution that may [...] Read more.
Increased interest is demonstrated recently in the emergence of prosumer schemes for the residential sector on the basis of combined RES and storage configurations. Primarily, such schemes aim to increase energy autonomy for end users. Despite providing an alternative supply solution that may secure end users from volatile energy prices, RES–battery configurations also suggest costly and, in most cases, capital-intensive solutions. As such, exploring the generation of additional revenue through market participation is an exercise worth undertaking, noting at the same time that decongestion management services may also be provided to the local grid. In this context, the current study introduces an operational framework for the market participation of RES–battery prosumer schemes, seeking to determine the optimal balance between self-consumption and market integration. For that purpose, we use typical demand patterns and perform an extensive parametrical analysis concerning system size, spot price levels and degree of market integration in the context of the Greek electricity market, with our results indicating areas of optimum balance for the minimization of similar schemes’ levelized cost of electricity. Full article
Show Figures

Figure 1

7 pages, 3431 KiB  
Proceeding Paper
Investigating the Impact of Cycling Aging on the Long-Term Performance of RES-Driven, Second-Life EV Battery Storage Configurations in Residential-Scale Applications
by Angelos Kaldellis, Konstantinos Christopoulos, Panagiotis Triantafyllopoulos, Georgios Spyropoulos, Kosmas Kavadias and Dimitrios Zafirakis
Environ. Sci. Proc. 2023, 26(1), 179; https://doi.org/10.3390/environsciproc2023026179 - 7 Sep 2023
Viewed by 1041
Abstract
Battery storage is nowadays considered a key component not only in off-grid applications but also in the context of grid-tied, residential-scale systems, facilitating the broader use of RES even in heavily congested distribution grids. Since batteries normally comprise the costliest part in similar [...] Read more.
Battery storage is nowadays considered a key component not only in off-grid applications but also in the context of grid-tied, residential-scale systems, facilitating the broader use of RES even in heavily congested distribution grids. Since batteries normally comprise the costliest part in similar configurations, their optimal sizing is a priority. Informed decisions to that end should not be limited to rough, initial-cost estimations alone; instead, they should also take into account the life-cycle costs of batteries, which, in turn, relate to battery aging mechanisms and the gradual, cycling-based fading of the batteries’ useful capacity. Acknowledging the above, the impact of battery cycling aging on the performance of typical, residential-scale, RES-based battery storage configurations is investigated herein, considering also the utilization of second-life lithium-ion EV batteries. To that end, we used a literature-informed empirical aging model and performed a simulation exercise for a broad set of different RES-battery configurations, with our results indicating the importance of the aging factor while also designating areas of optimum sizing with regard to the long-term energy and economic performance of similar solutions. Full article
Show Figures

Figure 1

7 pages, 3479 KiB  
Proceeding Paper
Stochastic Assessment of Day-Ahead, Wind Energy Curtailment-Driven Demand Response Requirements in Non-Interconnected Island Systems
by Dimitrios Zafirakis, Konstantinos Christopoulos, Konstantinos Moustris and John K. Kaldellis
Environ. Sci. Proc. 2023, 26(1), 176; https://doi.org/10.3390/environsciproc2023026176 - 6 Sep 2023
Viewed by 880
Abstract
Occurrence of wind energy curtailments in non-interconnected island systems of considerable wind power capacity comes as a result of local grid limitations and significant load variation across seasons. Facilitating increased wind energy generation requires flexibility means such as energy storage and/or demand response [...] Read more.
Occurrence of wind energy curtailments in non-interconnected island systems of considerable wind power capacity comes as a result of local grid limitations and significant load variation across seasons. Facilitating increased wind energy generation requires flexibility means such as energy storage and/or demand response (DR), with the latter presenting the advantage of suggesting a non-capital-intensive solution. To that end, in the present study we examine the problem of assessing day-ahead demand response requirements for the recovery of wind energy curtailments and put forward a stochastic approach, supported by the employment of artificial neural networks’ forecasting models and the integration of prediction uncertainties. For the application of our methodology, we use data from the non-interconnected island system of Kos and Kalymnos in the SE Aegean Sea and investigate the dynamics of the proposed DR scheme on the island of Tilos, belonging to the electricity complex of Kos and Kalymnos. At the same time, we perform a parametrical analysis so as to study the impact of appreciating different levels of available DR capacity, with our findings comparing favorably against the results of applying a deterministic approach. Full article
Show Figures

Figure 1

18 pages, 896 KiB  
Review
Tumor Markers and Their Diagnostic Significance in Ovarian Cancer
by Alkis Matsas, Dimitrios Stefanoudakis, Theodore Troupis, Konstantinos Kontzoglou, Makarios Eleftheriades, Panagiotis Christopoulos, Theodoros Panoskaltsis, Eleni Stamoula and Dimitrios C. Iliopoulos
Life 2023, 13(8), 1689; https://doi.org/10.3390/life13081689 - 5 Aug 2023
Cited by 47 | Viewed by 13143
Abstract
Ovarian cancer (OC) is characterized by silent progression and late-stage diagnosis. It is critical to detect and accurately diagnose the disease early to improve survival rates. Tumor markers have emerged as valuable tools in the diagnosis and management of OC, offering non-invasive and [...] Read more.
Ovarian cancer (OC) is characterized by silent progression and late-stage diagnosis. It is critical to detect and accurately diagnose the disease early to improve survival rates. Tumor markers have emerged as valuable tools in the diagnosis and management of OC, offering non-invasive and cost-effective options for screening, monitoring, and prognosis. Purpose: This paper explores the diagnostic importance of various tumor markers including CA-125, CA15-3, CA 19-9, HE4,hCG, inhibin, AFP, and LDH, and their impact on disease monitoring and treatment response assessment. Methods: Article searches were performed on PubMed, Scopus, and Google Scholar. Keywords used for the searching process were “Ovarian cancer”, “Cancer biomarkers”, “Early detection”, “Cancer diagnosis”, “CA-125”,“CA 15-3”,“CA 19-9”, “HE4”,“hCG”, “inhibin”, “AFP”, “LDH”, and others. Results: HE4, when combined with CA-125, shows improved sensitivity and specificity, particularly in early-stage detection. Additionally, hCG holds promise as a prognostic marker, aiding treatment response prediction and outcome assessment. Novel markers like microRNAs, DNA methylation patterns, and circulating tumor cells offer potential for enhanced diagnostic accuracy and personalized management. Integrating these markers into a comprehensive panel may improve sensitivity and specificity in ovarian cancer diagnosis. However, careful interpretation of tumor marker results is necessary, considering factors such as age, menopausal status, and comorbidities. Further research is needed to validate and refine diagnostic algorithms, optimizing the clinical significance of tumor markers in ovarian cancer management. In conclusion, tumor markers such as CA-125, CA15-3, CA 19-9, HE4, and hCG provide valuable insights into ovarian cancer diagnosis, monitoring, and prognosis, with the potential to enhance early detection. Full article
(This article belongs to the Special Issue Diagnosis and Treatment of Obstetrics and Gynecology Diseases)
Show Figures

Figure 1

17 pages, 780 KiB  
Review
Impact of Chemicals on the Age of Menarche: A Literature Review
by Xristos Anastasiadis, Alkis Matsas, Theodoros Panoskaltsis, Panagiotis Bakas, Dimitrios T. Papadimitriou and Panagiotis Christopoulos
Children 2023, 10(7), 1234; https://doi.org/10.3390/children10071234 - 17 Jul 2023
Cited by 7 | Viewed by 4634
Abstract
A growing body of evidence suggests that chemicals interfere with the age of onset of menarche. We conducted a review in order to demonstrate the relationship between several categories of chemicals and menarche. We searched for English language papers using the Medline/PubMed database [...] Read more.
A growing body of evidence suggests that chemicals interfere with the age of onset of menarche. We conducted a review in order to demonstrate the relationship between several categories of chemicals and menarche. We searched for English language papers using the Medline/PubMed database until April 2023. The chemical factors found to affect menarche were prenatal and antenatal smoke, phthalates, phenols, organochlorines, perfluoroalkyls and polyfluoroalkyls, metals, air pollutants and polybrominated diphenyl ethers. Low or high exposure to each chemical compound could affect the age of menarche, leading to early or delayed menarche. Furthermore, the results show that intrauterine exposure may have a different impact from antenatal exposure. There is evidence that endocrine-disrupting chemicals affect the age of menarche, but more research needs to be conducted. Full article
(This article belongs to the Special Issue New Trends in Adolescent Health and Development)
Show Figures

Figure 1

8 pages, 601 KiB  
Case Report
A Novel Variant in the TP53 Gene Causing Li–Fraumeni Syndrome
by Dimitrios T. Papadimitriou, Constantine A. Stratakis, Antonis Kattamis, Stavros Glentis, Constantine Dimitrakakis, George P. Spyridis, Panagiotis Christopoulos, George Mastorakos, Nikolaos F. Vlahos and Nicoletta Iacovidou
Children 2023, 10(7), 1150; https://doi.org/10.3390/children10071150 - 30 Jun 2023
Cited by 2 | Viewed by 2692
Abstract
Li–Fraumeni syndrome (LFS) is an autosomal dominant hereditary cancer syndrome associated with germline pathogenic variants in the tumor protein p53 (TP53) gene and elevated risk of a broad range of early-onset malignancies. Patients with LFS are at risk of a second [...] Read more.
Li–Fraumeni syndrome (LFS) is an autosomal dominant hereditary cancer syndrome associated with germline pathogenic variants in the tumor protein p53 (TP53) gene and elevated risk of a broad range of early-onset malignancies. Patients with LFS are at risk of a second and third primary tumor. A 15-month-old girl consulted for clitoromegaly and pubic hair. Adrenal ultrasound detected a large left adrenal tumor. Left total adrenalectomy confirmed adrenocortical carcinoma. Family history revealed multiple highly malignant neoplasms at an early age across five generations, and a genetic dominant trait seemed probable. Whole-genome sequencing was performed. Multiple members of the family were found positive for a novel likely pathogenic variant (c. 892delGinsTTT, p. Glu298PhefsX48, NM_000546.6) in the TP53 gene, causing the loss of normal protein function through non-sense-mediated mRNA decay. According to the PSV1 supporting criteria and the Auto PVS1 online tool this frameshift variant: hg19/17-7577045-TC-TAAA:NM_000546.6 has a very strong, definitive clinical validity for LFS with autosomal dominant inheritance. Proper guidance resulted in timely diagnosis of a second tumor (primary osteosarcoma) in the index case and in the early detection of breast and cervical cancer in her young mother. Patients with cancer predisposition syndromes like LFS require close multidisciplinary cancer surveillance and appropriate referral to expert centers. Full article
Show Figures

Figure 1

14 pages, 299 KiB  
Review
Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review
by Maria Effrosyni Livanou, Alkis Matsas, Serena Valsami, Dimitrios T. Papadimitriou, Athanasios Kontogiannis and Panagiotis Christopoulos
Life 2023, 13(6), 1321; https://doi.org/10.3390/life13061321 - 5 Jun 2023
Cited by 2 | Viewed by 3744
Abstract
Clotting Factor deficiencies are rare disorders with variations in clinical presentation and severity of symptoms ranging from asymptomatic to mild to life-threatening bleeding. Thus, they pose a diagnostic and therapeutic challenge, mainly for the primary health care providers, general practitioners, and gynecologists who [...] Read more.
Clotting Factor deficiencies are rare disorders with variations in clinical presentation and severity of symptoms ranging from asymptomatic to mild to life-threatening bleeding. Thus, they pose a diagnostic and therapeutic challenge, mainly for the primary health care providers, general practitioners, and gynecologists who are more likely to first encounter these patients. An additional diagnostic challenge arises from the variable laboratory presentations, as PT, PTT, and BT are not always affected. The morbidity is higher among women of reproductive age since Abnormal Uterine Bleeding–specifically Heavy Menstrual Bleeding–is one of the most prevalent manifestations of these disorders, and in some cases of severe deficiencies has led to life-threatening episodes of bleeding requiring blood transfusions or even immediate surgical intervention. Physician awareness is important as, in the case of some of these disorders–i.e., Factor XIII deficiency–prophylactic treatment is available and recommended. Although uncommon, the potential for rare bleeding disorders and for hemophilia carrier states should be considered in women with HMB, after more prevalent causes have been excluded. Currently, there is no consensus on the management of women in these instances and it is reliant on the physicians’ knowledge. Full article
Back to TopTop